N-cadherin is a cell --cell adhesion molecule that plays a role in breast cancer metastasis. Here, we show that in vivo expression of N-cadherin in the PyMT mouse model, which enhances mammary tumor metastasis, results in selective inhibition of Akt3 expression and phosphorylation. Similarly, exogenous expression of N-cadherin in PyMT or MCF-7 mammary tumor cells enhanced cell motility and caused a dramatic reduction in Akt3 expression and phosphorylation. Moreover, knockdown of Akt3 in PyMT tumor cells increased cell motility and disrupted mammary morphogenesis, but had no effect on cell proliferation. Conversely, overexpression of wild-type Akt3 in PyMT-N-cadherin cells inhibited cell motility promoted by N-cadherin. Taken altogether, these findings demonstrate that N-cadherin suppresses Akt3 to promote cell motility and highlight the intricate regulation of Akt isoforms by N-cadherin during metastasis.
INTRODUCTION
Metastasis is a multi-step process where tumor cells migrate away from a primary tumor to grow at a distant site. For tumor cells to successfully metastasize, they must acquire the ability to detach from the primary tumor, invade into the extracellular matrix, intravasate into lymphatic or blood vessels, extravasate out into a distant site and form secondary tumors.
1 Cell --cell adhesion is a critical process that regulates metastasis through key modulators such as the classical cadherins, especially E-cadherin and N-cadherin.
2 --4 E-cadherin is expressed in epithelial tissues where it maintains strong cell --cell adhesion and tissue architecture and is thus often reduced during malignant progression. 2 On the contrary, N-cadherin, which is prevalent in neurons and mesenchymal tissues, 4 has been found to be upregulated in invasive breast cancer cell lines 5 and breast tumors, especially in the metastasis-prone micropapillary breast carcinoma. 6 Upregulation of N-cadherin in malignant cells was shown to enhance cell motility, invasion and metastasis. 7 --10 The mechanism whereby N-cadherin promotes metastasis is likely to be complex but one possibility involves the regulation of oncogenic signaling pathways. 3 We have shown that N-cadherin expression in MCF-7 cells promotes metastasis by enhancing extracellular-signal-regulated kinase (ERK) phosphorylation that leads to matrix metallopeptidase-9 upregulation and increased tumor cell invasion. 8, 9 These findings were corroborated in vivo, where de novo expression of Ncadherin in the MMTV-PyMT mouse model of mammary tumorigenesis enhanced metastasis partly because of increased ERK activation and matrix metallopeptidase-9 expression. 10 Interestingly, whereas ERK inhibition suppressed invasion, it had no effect on cell migration, suggesting that N-cadherin uses another pathway to regulate cell migration. 10 Indeed, we observed that Akt phosphorylation was decreased in PyMT-N-cadherin cells compared with PyMT control cells, thus suggesting that N-cadherin attenuates the Akt pathway to increase cell motility. 10 The Akt pathway involves three distinct isoforms, Akt1, Akt2 and Akt3, which were shown to differentially regulate cell proliferation, motility and invasion. 11, 12 Whereas Akt2 promotes tumor cell motility and epithelial-to-mesenchymal transition, Akt1 suppresses these processes. 13, 14 Whereas several studies have addressed the role of Akt1 and Akt2 in tumor progression, little is known about Akt3. Here we report in vivo in the PyMT-N-cadherin breast cancer metastasis model that N-cadherin enhances motility by suppressing Akt3 function. We show that N-cadherin expression in the PyMT and MCF-7 mammary tumor cells has no effect on Akt1 or Akt2 but selectively suppresses Akt3 expression. In addition, we demonstrate that knockdown of Akt3 in PyMT tumor cells increased cell motility and disrupted mammary morphogenesis, but had no effect on tumor cell proliferation. Conversely, increased expression of wild-type Akt3 in PyMT-N-cadherin tumor cells inhibited cell motility while having no effect on cell proliferation. Therefore, our study suggests that N-cadherin suppresses Akt3 to promote tumor cell motility during metastasis.
RESULTS
In vivo mammary expression of N-cadherin in the MMTV-PyMT transgenic breast tumor model suppresses Akt3 expression and phosphorylation We previously observed an inverse relationship between ERK and Akt phosphorylation in N-cadherin-expressing PyMT mammary tumor cells (PyMT-N-cad) derived from the highly metastatic PyMT-N-cadherin bi-transgenic mouse. Namely, whereas ERK phosphorylation was increased in PyMT-N-cad cells, Akt phosphorylation was decreased relative to control PyMT cells. 10 Given the intricate interplay between the Akt isoforms in tumor progression, we sought to determine whether N-cadherin alters the expression of specific Akt isoforms in PyMT-N-cad cells. Independent heterogeneous pools of mammary tumor epithelial cells were generated from three PyMT and PyMT-N-cad mice. These tumors were at 7 weeks post tumor onset because at this time point PyMT-N-cad mice exhibited a 3.5-fold increase in metastasis compared with PyMT mice. 10 It is important to note that the mammary tumor cell lines were used only once after 4 days in culture to minimize in vitro artifacts. These cell lines were analyzed for their expression of N-cadherin, E-cadherin and PyMT by immunoblotting to confirm their tumorigenic epithelial origin. As expected, N-cadherin expression was increased in PyMT-N-cad cells compared with PyMT cells, whereas E-cadherin levels were unchanged (Figure 1a) . The expression of PyMT, a viral oncoprotein that drives tumorigenesis in this model, was also comparable ( Figure 1a) . Next, the levels of the individual Akt isoforms were assessed with isoform-specific Akt antibodies and relative expression levels were assessed by densitometry. Although Akt1 and Akt2 expression was similar in PyMT and PyMT-N-cad cells (Figures 1a and b) , Akt3 was significantly decreased in PyMT-N-cad cells relative to PyMT cells (Figures 1a and b) .
Clonal epithelial cell lines were also derived from PyMT and PyMT-N-cad mammary tumors at 7 weeks post tumor onset. These cell lines were maintained in culture for further analysis of the regulation of Akt3 expression by N-cadherin. Four PyMT-N-cad clones were analyzed; all showed similar increases in N-cadherin and unchanged levels of E-cadherin compared with PyMT control clones ( Figure 2a ). Consistent with observations made in heterogeneous pools, PyMT-N-cad clonal cell lines exhibited a significant decrease in Akt3 expression, but did not show any changes in Akt1 or Akt2 expression (Figures 2a and b) .
We also assessed the phosphorylation levels of Akt3 in these cell lines using antibodies that recognize two regulatory sites, Ser472 and Thr305. 15 To specifically detect Akt3 phosphorylation, Akt3 immunoprecipitates from PyMT and PyMT-N-cad cell extracts were immunoblotted with anti-phospho-Akt Ser472 and Thr305 or anti-Akt3. The phosphorylation of Akt3 at both Ser472 and Thr305 sites was significantly decreased in the PyMT-N-cad cells compared with PyMT cells (Figures 2c and d) . The decrease in Akt3 phosphorylation in PyMT-N-cad cells was equivalent to the decrease in total Akt3 levels, as shown by a densitometric ratio of 1.0 between phosphorylated and total Akt3 levels (Figure 2e) , suggesting that the phosphorylation of Akt3 is suppressed because of decreased Akt3 expression.
Exogenous expression of N-cadherin in a PyMT mammary tumor cell line reduces Akt3 expression and phosphorylation To further confirm that N-cadherin suppresses Akt3 expression, a myc-tagged N-cadherin construct (N-cad-Myc) or control vector was transduced into a PyMT clonal cell line. PyMT-N-cad-Myc cells positive for N-cad membrane expression were isolated by fluorescence-activated cell sorter analysis using an extracellular N-cad-specific antibody. Immunofluorescence analysis revealed that high levels of N-cadherin were present at cell --cell contacts in PyMT-N-cad-Myc cells as compared with low levels in PyMT control cells (Figure 3a) . In both control PyMT and PyMT-N-cadMyc cells, E-cad was predominantly present at the membrane (Figure 3a) , further suggesting that expression of N-cad does not displace E-cad from cell --cell contacts. These observations were validated by western blot analysis that demonstrated that ectopic N-cad-Myc expression had no effect on either E-cad or PyMT expression (Figure 3b ). The effects of ectopic N-cad-Myc on the expression of Akt isoforms were also analyzed. Once again, Akt1 and Akt2 expression remained unchanged but Akt3 expression was decreased when comparing PyMT-N-cad-Myc cells with PyMT control cells (Figure 3b) . Furthermore, immunoblot analysis of Akt3 immunoprecipitates showed that Akt3 phosphorylation at Ser472 and Thr305 was reduced in PyMT-N-cad-Myc cells relative to PyMT control cells (Figure 3c) . Again, the decrease in Akt3 phosphorylation was proportional to the decrease in Akt3 To further validate that the effects of N-cadherin on Akt3 expression were not because of confounding effects from other cadherins present in mammary epithelial cells such as R-cadherin, 16 we transfected N-cad-Myc into mouse L cells that are fibroblasts devoid of endogenous cadherins. In these cells, N-cad was also found to downregulate Akt3 expression without affecting Akt1 or Akt2 levels compared with control vector-transfected L cells (Figure 3e ). These data, in combination with our findings in PyMT-N-cad cells, strongly suggest that N-cadherin selectively suppresses Akt3 expression and hence phosphorylation.
To confirm the relationship between N-cadherin and Akt3 in human breast cancer cells, we expressed N-cadherin in MCF-7 cells. We found that transfection of a tetracycline-repressible human N-cadherin vector into MCF-7 cells induced N-cadherin and reduced Akt3 expression 24 h following tetracycline withdrawal from the growth media ( Figure 4a N-cadherin reduces Akt3 mRNA but has no effect on Akt3 protein stability Given that N-cadherin has an inhibitory effect on Akt3 expression, we examined whether this effect occurred at the transcriptional or post-translational level. Akt3 mRNA levels in two PyMT and PyMT-N-cadherin clonal cell lines (PyMT1, PyMT2, PyMT-N-cad1 and PyMT-N-cad2) were assessed by realtime quantitative PCR. One out of the two PyMT-N-cadherin cell lines exhibited a modest, yet significant, decrease in Akt3 mRNA levels compared with PyMT cells (Supplementary Figure 1A) . In addition, PyMT-N-cad-Myc cells also had a slightly lower level of Akt3 mRNA than PyMT-control vector cells (Supplementary Figure 1B) . These data suggest that transcriptional regulation may be a partial mechanism by which N-cadherin suppresses Akt3 expression.
Next, we examined whether N-cadherin expression affects Akt3 protein stability. PyMT and PyMT-N-cad clonal cell lines were treated with the protein synthesis inhibitor cycloheximide for 0, 2, 4 and 8 h. Extracts from these cells were then western blotted for Akt3. PyMT-N-cad cell lines exhibited similar Akt3 degradation rate as PyMT cell lines (Supplementary Figure 1C) . We also performed the same experiment on PyMT-control vector cells and PyMT-N-cad-myc cells and found that the degradation rate of Akt3 was comparable between the two cell lines (Supplementary Figure 1D) . Altogether, these data indicate that N-cadherin modestly affects the expression of Akt3 at the transcriptional level but not at the post-translational level. Similar effects on Akt3 mRNA expression and protein stability were obtained in N-cadherin-expressing L cells relative to vector-transfected cells (not shown). N-cadherin suppression of Akt3 expression is independent of FGFR As N-cadherin was shown to mediate invasion by potentiating fibroblast growth factor receptor (FGFR) signaling, 8 --10 we speculated that N-cadherin may regulate Akt3 expression through the FGFR pathway. We thus tested whether inhibition of FGFR1 by the FGFR1 tyrosine kinase inhibitor, PD173074, 17 restores Akt3 expression. Treatment of PyMT-N-cad cells with PD173074 at 0.1 --0.5 mM, which efficiently reduced FRS2 and ERK phosphorylation, 18 had no effect on Akt3 expression (Supplementary Figure 2) . These data suggest that N-cadherin regulates Akt3 expression in an FGFR-independent manner.
Akt3 knockdown in PyMT cell lines increases cell migration and disrupts mammary acinar morphogenesis Several studies have demonstrated that Akt isoforms regulate cell motility. 11, 12 Given that we previously showed that expression of N-cadherin in PyMT cells promotes motility, 10 and that we have presently found that N-cadherin specifically suppresses Akt3, we examined the effects of decreased Akt3 expression on cell motility. Three independent Akt3 microRNA-adapted shRNA (shRNAmir) (Figure 5a ), whereas they had no effect on the expression of Akt1 or Akt2 (Figure 5a ). The effect of Akt3 knockdown by shRNAmir-2 or -3 on cell migration was determined in transwell motility assays. PyMT cell lines expressing either Akt3 shRNAmir-2 or -3 exhibited a 1.7-and a 1.8-fold increase in cell motility, respectively, compared with control cells (Figure 5b ).
Considering that Akt isoforms have been shown to be involved in cell proliferation and survival, 15 we analyzed the effects of Akt3 knockdown on these processes in the PyMT cell lines. Growth curves performed for PyMT cell lines transduced with control vector, Akt3 shRNAmir-2 or -3 showed that both Akt3 knockdown cell lines exhibited similar growth rates as compared with control cells (Figure 5c ). These data suggested that Akt3 does not affect cell proliferation, implying that N-cad attenuates Akt3 expression to enhance cell motility. It has been shown that Akt1 and Akt2 have distinct effects on mammary acinar morphogenesis. 13 We therefore examined whether Akt3 knockdown would affect the formation of mammary acini in three-dimensional Matrigel cultures. We cultured the PyMT cell lines transduced with control shRNAmir, Akt3shRNAmir-2 or -3 in Matrigel for 10 days. Matrigel cultures were fixed and stained with phalloidin to visualize the actin cytoskeleton and changes in morphogenesis (Figure 5d) . Using confocal microscopy, we found that compared with control PyMT cells that formed compact spheroids with cortical actin belts, PyMT cells transduced with either Akt3 shRNAmir-2 or -3 were unable to assume a full acinar structure (Figure 5d ). These results suggest that Akt3 loss disrupts mammary morphogenesis.
These results were further reproduced in another PyMT cell line, in which Akt3 shRNAmir-3, which caused the most dramatic knockdown of Akt3 without affecting Akt1 or Akt2 (Figure 6a ), caused a 2.5-fold increase in cell motility (Figure 6b ). Although Akt3 shRNAmir-3 enhanced migration, it did not affect cell growth or viability (Figure 6c ). Moreover, Akt3 shRNAmir-3 caused PyMT cells to form aberrant acini in Matrigel as compared with control cells that formed intact acini (Figure 6d ). Taken together, these data suggest that Akt3 suppresses malignant Overexpression of Akt3 in PyMT-N-cad cells inhibits cell motility Having found that Akt3 inhibits cell motility, we hypothesized that Akt3 played a role in N-cadherin-induced motility. As shown earlier, N-cadherin suppresses Akt3 expression and subsequently the phosphorylation of Akt3. To determine whether activation of Akt3 inhibits N-cad-mediated motility, we generated a PyMT-Ncad cell line expressing wild-type Akt3 using a lentiviral expression vector. By western blotting, we confirmed that PyMT-N-cad-Akt3 cells had increased expression of Akt3 (Figure 7a ) but unchanged Akt1 or Akt2 expression relative to PyMT-N-cad control cells (Figure 7a) . To analyze the migration of PyMT-N-cad-Akt3 cells relative to control cells, we first performed transwell migration assays. Interestingly, Akt3 expression dramatically suppressed motility as compared with PyMT-N-cad control cells (Figure 7b ). Similar results were obtained when cell migration was measured by a time-lapse epidermal growth factor (EGF) chemotaxis assay (Figure 7c) . PyMT-N-cad-Akt3 and PyMT control cells were serum starved and stimulated with EGF for 30 min. EGF-treated PyMT-Ncad cells expressing Akt3 exhibited dramatically reduced chemotaxis as compared with PyMT-N-cad control cells that were highly motile (Figure 7c ). In this assay, there was however no change in motile behavior between untreated cells from control and Akt3-overexpressing PyMT-N-cad cells (Figure 7c) . To dissociate the effects of Akt3 on cell motility from those on cell proliferation, we measured 5-bromodeoxyuridine (BrdU) incorporation in these cell lines. We found no differences in BrdU uptake between Akt3 and control vector expressing PyMT-N-cad cells, indicating that Akt3 suppresses motility but has no effect on cell proliferation (Figure 7d) , consistent with the effect of Akt3 knockdown on these processes.
DISCUSSION
We have previously shown that mammary expression of N-cadherin in the PyMT mammary tumor model enhances tumor cell motility, invasion and metastasis in vivo. N-cadherin was shown to constitutively activate the ERK pathway that led to matrix metallopeptidase-9 upregulation and tumor cell invasion. 10 Interestingly, although invasion was dependent on ERK activation, N-cadherin-induced motility was not, suggesting that invasion and motility are governed by distinct signaling events. 10 Indeed, the findings from this study show that N-cadherin regulates the Akt pathway to enhance tumor cell migration via Akt3 suppression.
We found that N-cadherin expression into the MMTV-PyMT mouse, which enhances metastasis, suppresses Akt3 expression in primary tumors, suggesting Akt3 regulation by N-cadherin occurs in vivo. Suppression of Akt3 by N-cadherin appears to be direct as ectopic expression of N-cadherin in PyMT cells, MCF-7 cells and finally in L cells that do not contain any other cadherins dramatically reduced Akt3 expression. This downregulation of Akt3 resulted in a decrease in Akt3 phosphorylation, suggesting that Akt3 activity is important for motility suppression. Interestingly, N-cadherin selectively targeted Akt3 as it had no effect on the expression of either Akt1 or Akt2.
Our data showed that N-cadherin had no effect on Akt3 protein stability but caused a modest decrease in Akt3 mRNA levels, suggesting a mild effect on Akt3 gene transcription. However, this alone is unlikely to account for the large reduction in Akt3 protein expression. We thus speculate that N-cadherin may modulate Akt3 expression at the translational level possibly through the regulation of microRNAs that have been shown to regulate other Akt isoforms. 19 Thus, the likelihood that N-cadherin attenuates Akt3 expression via the regulation of microRNAs remains to be determined.
As N-cadherin was shown to mediate metastasis by potentiating FGFR signaling, 8 --10 we speculated that N-cadherin may regulate Akt3 through the FGFR pathway. However, inhibition of FGFR by PD173074 in PyMT-N-cad cells, which was previously shown to reduce tumor motility and invasion, 10 did not reverse Akt3 suppression. These data suggest that N-cadherin regulates Akt3 expression in an FGFR-independent manner.
Several studies have shown that Akt1 inhibits motility whereas Akt2 promotes it in breast cancer cells. 11, 12 However, little is known about the function of Akt3 in tumor progression. We are the first to demonstrate a function for Akt3 in breast cancer and to link it to tumor cell migration. We propose that downregulation of Akt3 may be one mechanism by which N-cadherin enhances metastasis in the PyMT mammary tumor model. N-cadherin expression in this model enhanced metastasis without affecting primary tumor growth. 10 Consistent with these findings, knockdown of Akt3 in PyMT cells increased cell motility without affecting cell proliferation. In three-dimensional Matrigel cultures, knockdown of Akt3 in PyMT cell lines disrupted acinar morphogenesis, which might be caused by weakened cell --cell adhesion associated with the motile phenotype.
Our findings clearly show that Akt3 signaling regulates cell migration. In further support of this idea, we showed that expression of Akt3 in PyMT-N-cad cells markedly reduced cell migration. These results are consistent with the inhibition of cell motility observed in melanoma cells exogenously expressing myristoylated Akt3. 20 Our data demonstrate that N-cadherinstimulated motility can be reversed by enhancing Akt3 expression.
Although we have shown that Akt3 inhibits motility, the mechanism by which Akt3 regulates this process remains unknown. Previous studies have demonstrated that the Akt isoforms can modulate motility via the regulation of oncogenic signaling. 21 Akt1 has been shown to suppress breast cancer cell migration by inhibiting ERK, which is known to regulate transcription of pro-motility genes. 13 However, we have not found a link between Akt3 and ERK activity in the PyMT-N-cad model. Akt3 knockdown in PyMT cells did not activate ERK (not shown), consistent with that ERK inhibition in PyMT-N-cad cells did not affect cell motility. 10 Given that Akt3 and Akt1 may be functionally redundant as both isoforms were shown to inhibit breast cancer cell migration, it is not clear how Akt1 does not compensate for Akt3 loss in tumor cells. This raises the question of whether Akt3 and Akt1 share common or independent mechanisms. Both Akt1 and Akt3 were shown to phosphorylate glycogen synthase kinase-3b and Foxo1, 22 suggesting that these isoforms may signal through the same pathway to modulate migration. Thus, if Akt1 and Akt3 share common pathways, then N-cadherin might inhibit motility by lowering the combined activity of Akt1 and Akt3. On the other hand, Akt3 and Akt1 may use independent mechanisms to regulate motility. In support of this notion, Akt1, and not Akt2, has been shown to associate with and phosphorylate the actinbundling protein palladin, 23 suggesting that the Akt isoforms may be involved in isoform-specific protein --protein interactions, and thus impart distinct signaling events. 12 Others have investigated the effect of Akt3 knockout on PyMT and ErbB2 models and failed to find striking effects for Akt3 on tumorigenesis or metastasis. 24 These models may however not truly reflect the role of Akt3 in vivo as Akt3 was deleted in all tissues. Akt3 has been shown to contribute to tumor-stroma paracrine signaling, and hence these mouse models do not discriminate the tumor cell autonomous effects from the stromal effects of Akt3.
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This study and previous ones highlight the fact that Akt isoforms having opposing effects on cell proliferation, invasion and migration, and thus a more thoughtful and controlled approach should be taken in the clinical application of Akt inhibitors. As both N-cadherin and Akt3 may be potential targets for breast cancer treatment, our study contributes to the understanding of how drugs can be better developed to effectively treat breast cancer.
MATERIALS AND METHODS

Animals and generation of mammary tumor cells
The MMTV-PyMT and PyMT-N-cadherin mice have been previously described. 25, 26 Mammary tumor cells were isolated from PyMT-N-cad mice at 7 weeks post tumor onset. 10 All animal experiments were performed according to a protocol approved by the institutional animal care and use committee at Albert Einstein College of Medicine. the cytomegalovirus promoter between the Xho1/Xba1 restriction sites. For production of shRNAmirs for mouse Akt3, three independent mouse Akt3 shRNAmirs in the pGIPZ lentiviral vector were purchased from Open Biosystems (Huntsville, AL, USA) . A pGIPZ non-silencing shRNA mir vector along with Tat, Rev, Gag/Pol and VSV-G packaging vectors were obtained from Dr Jeffery Segall (Albert Einstein College of Medicine, NY, USA). The pcL-ampho packing vector was obtained from Dr Stuart Aaronson (Mount Sinai School of Medicine, NY, USA). Cells were transfected with appropriate retroviral vector using Lipofectamine LTX reagent (Invitrogen, Grand Island, NY, USA). After 48 h, cells were selected with puromycin (2 mg/ml) or geneticin (400 mg/ml). To generate viruses, retroviral and lentiviral vectors were transfected into 293T cells with either the pCL-Ampho vector or Tat, Rev, Gag/Pol and VSV-G vectors, respectively, for 48 h. Viral supernatant was used to transduce cells that were selected with puromycin (2 mg/ml) or geneticin (400 mg/ml). Cells transduced with N-cad-Myc were further selected for N-cadherin expression by fluorescence-activated cell sorting using an N-cadherin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Tetramethyl Rhodamine Iso-Thiocyanate (TRITC)-conjugated secondary antibody (Invitrogen).
Constructs, transfection and transduction
Western blot and immunoprecipiation
Protein (30 mg) was run on a 10% SDS --PAGE gel and transferred to polyvinylidene difluoride membrane. Blots were probed with appropriate primary antibodies and then incubated with horseradish peroxidaseconjugated secondary antibodies. Blots were developed with chemiluminescence. Akt3 immunoprecipitations were performed by incubating Akt3 antibody with cell lysates overnight at 4 1C with gentle rotation. The next day, protein G-agarose beads were added for 3 h, washed with 1% Triton lysis buffer and eluted in boiling 1 Â SDS buffer. The antibodies used were as follows: N-cadherin or E-cadherin (BD Transduction Laboratories, San Diego, CA, USA); Akt1, Akt2, Akt3, p-Akt (Ser473), p-Akt (Thr308) p-ERK, ERK and P-FRS2 (Cell Signaling Technology, Danvers, MA, USA); PyMT (Dr Steve Dillworth, Imperial College, London, UK); and Actin (Sigma, St Louis, MO, USA). Band intensity was quantified by ImageJ 1.34s (NIH, Bethesda, MD, USA). Statistical significance was determined using the two-tailed t-test at P-values o0.05.
Immunostaining
Cells attached to collagen-coated coverslips were fixed with 3.7% paraformaldehyde for 10 min, permeabilized with 0.02% Triton for 2 min and blocked with 2% bovine serum albumin buffer for 1 h, incubated with N-cadherin and E-cadherin primary antibodies for 1 h and then incubated with fluorescein isothiocyanate-conjugated and TRITC-conjugated secondary antibodies (Invitrogen) for 1 h. Images were taken using Zeiss Axioskop 2 microscope (Zeiss, Thornwood, NY, USA).
Real time-PCR
RNA was isolated using Trizol reagent (Invitrogen) following the manufacturer's protocol. Akt3 Taqman -primers and RNA-to-CT 1-Step Kit were purchased from Applied Biosystems (Carlsbad, CA, USA), and realtime PCR experiments were performed using a StepOnePlus real-time PCR instrument from Applied Biosystems. GAPDH was used as reference gene and relative mRNA levels were determined using the 2 (ÀDDCt) method. Three independent experiments were performed. Statistical significance was tested by the two-tailed t-test at P-values o0.05.
Transwell migration assay
PyMT cells (5 Â 10 4 ) in 0.5 ml Dulbecco's modified Eagle's medium/0.2% bovine serum albumin were plated onto a 24-well transwell chamber with 8 mM pore size (BD Biosciences, Bedford, MA, USA) and allowed to migrate for 16 h. As chemoattractant, 10% fetal bovine serum/Dulbecco's modified Eagle's medium was used. Cells that did not migrate were wiped away, and cells that migrated were stained with 4,6-diamidino-2-phenylindole and imaged. Cells from seven Â 20 microscopic fields were counted per chamber. Triplicates of three independent experiments were performed. Statistical significance by the two-tailed t-test was at P-values o0.05.
Cell viability assay
PyMT cells (0.4 Â 10 4 ) in 100 ml growth media were plated into 96-well plates for 5 days. Cell viability was assessed by using CellTiter-Blue reagent (Promega, Madison, WI, USA). Briefly, CellTiter-Blue reagents were added to cells at indicated times for 1 h. Cell viability was then quantified by measuring the fluorescence signal emitted from the conversion of resazurin to resorufin in live cells, and was measured at excitation/ emission wavelength of 560/590 nm. Background signal emitted from wells containing only culture medium were subtracted from experimental values.
Growth curves and BrdU incorporation
For growth kinetics, cells were plated in triplicate wells in six-well plates at 5 Â 10 4 , and viable cells were trypsinized and counted each day for 8 days. The mean number of cells from triplicate wells ± s.e.m. is presented for each time point. Po0.05, two tailed t-test. For BrdU uptake, cells were grown on coverslips and 18 h later were pulsed with 10 mM of BrdU for 2 h. Cells were fixed and stained with anti-BrdU fluorescein isothiocyanatecoupled antibody. The percentage of BrdU-positive cells was determined in 10 fields of 500 cells per sample. The fraction of cells staining for BrdU was plotted as mean±s.e.m. in triplicates; Po0.05, two-tailed t-test.
Growth in Matrigel and immunostaining of acini
The embedding and growth of cells in Matrigel was performed as described. 27 For immunostaining, cultures were fixed in 4% paraformaldehyde for 30 min, permeabilized in 0.5% Triton-X-100 for 5 min and blocked in 2% bovine serum albumin/phosphate-buffered saline. Acini were stained with Alexafluor594 phalloidin (Invitrogen) for 30 min at 1:500 dilution, followed by washes in phosphate-buffered saline, counterstained with 4,6-diamidino-2-phenylindoleI and imaged by confocal microscopy.
Time lapse assay
Cells were plated at low density on MatTek dishes (Ashland, MA, USA). At 6 h before the experiment, cells were serum starved. Cells were either treated with EGF (100 ng/ml) by micropipette or untreated. Cells were imaged at Â 40 for 30 min at 1 min intervals with the Axiovision Rel 4.7 program (Zeiss). The movement of cells was measured using the NIS elements from Nikon (Tokyo, Japan). Statistical significance used two-tailed t-test with P-values o0.05.
